immunotherapy

Quibim Announces New Board of Directors To Promote Growth And Strategic ExpansionQuibim Announces New Board of Directors To Promote Growth And Strategic Expansion

Quibim Announces New Board of Directors To Promote Growth And Strategic Expansion

NEW YORK & VALENCIA, Spain & CAMBRIDGE, England--(BUSINESS WIRE)--#AIinHealthcare--Quibim, the global pioneer in imaging biomarkers for precision medicine, is pleased…

1 month ago
Global Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation’s 2025 Scientific SymposiumGlobal Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation’s 2025 Scientific Symposium

Global Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation’s 2025 Scientific Symposium

NEW YORK, April 3, 2025 /PRNewswire/ -- The Mark Foundation for Cancer Research convened more than 150 scientists from 13 states…

1 month ago
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisEnlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to…

1 month ago
Greenwich LifeSciences Provides Global Update on FLAMINGO-01Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…

1 month ago
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3,…

1 month ago
Kanazawa University research: New Breakthrough in Cancer Treatment: Tiny Vesicles Help the Immune System Fight TumorsKanazawa University research: New Breakthrough in Cancer Treatment: Tiny Vesicles Help the Immune System Fight Tumors

Kanazawa University research: New Breakthrough in Cancer Treatment: Tiny Vesicles Help the Immune System Fight Tumors

KANAZAWA, Japan, April 3, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University and colleagues have developed a…

1 month ago
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma PatientsCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of…

1 month ago
Coherus Announces Repurchase of Approximately $170 Million of Convertible NotesCoherus Announces Repurchase of Approximately $170 Million of Convertible Notes

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif.,…

1 month ago
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business UpdatePhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile…

1 month ago
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker ResearchLunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research

Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research

Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL,…

1 month ago